2238 Wagner, John L. - Thomas Jefferson University - Thomas Jefferson University
Dr. Wagner

John L. Wagner, MD

Contact Dr. Wagner

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Canine immunogenetics
  2. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  3. Adenovirus DNA polymerase is recognized by human CD8+ T cells
  4. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  5. Port site metastasis of B-cell lymphoma: A first occurrence or an underreported complication?
  6. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  7. Sequence of the canine major histocompatibility complex region containing non-classical class I genes
  8. Cytoprotection in acute myelogenous leukemia (AML) therapy
  9. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
  10. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  11. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation
  12. Molecular Organization of the Canine Major Histocompatibility Complex
  13. Cellular, serological, and molecular polymorphism of the class I and class II loci of the canine major histocompatibility complex
  14. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches
  15. Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee
  16. Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclat 07EF ure Committee
  17. Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism
  18. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
  19. Use of screening studies to predict survival among patients who do not have chronic graft-versus-host disease at day 100 after bone marrow transplantation
  20. Linezolid in the treatment of vancomycin resistant enterococcus infections in allogeneic stem cell transplant patients
0